This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Solid tumor	Bcl2 homology domain 3 (BH3)	<i>In vitro</i> and mouse studies suggest that a BH3 mimetic could sensitize hypoxic tumor cells to apoptosis to help treat solid tumors. In cancer cell lines, a BH3 mimetic increased apoptosis under hypoxic conditions compared with nonhypoxic conditions and worked in combination with chemotherapy to induce cell death. In mice with cancer xenografts, the mimetic decreased tumor size and induced apoptosis compared with vehicle control. Next steps could include testing the BH3 mimetic with vascular-targeted drugs in animal models of cancer.	Patent and licensing status unavailable	Harrison, L.R.E. <i>et al. J. Clin. Invest.</i> ; published online Feb. 14, 2011; doi:10.1172/JCI43505 Contact: Caroline Dive, Paterson Institute for Cancer Research, Manchester, U.K. e-mail: cdive@picr.man.ac.uk
<i>SciBX</i> 4(9); doi:10.1038/scibx.2011.254 Published online March 3, 2011				